Skip to main content
PAINWeek 2022 Main banner
Icon Legend
This session is not in your agenda.
This session is in your agenda. Click to remove it

Full Schedule

  1. Home
  2. Full Schedule
Sort by Full Schedule      Sort by Title      Sort by Track      Sort by Faculty  

Full Schedule

  • Cancelled
  • 18 Month Outcomes from Multicenter RCT: Spinal Cord Stimulation at 10kHz for Non-Surgical Refractory Back Pain
  • A call for implementation of transitional pain services within the perioperative setting: Using a commercial digital telehealth platform to overcome barriers
  • A Comparison of Definitive Urine Drug Test Results for Illicit Drugs in a Sample of People With Chronic Pain Prescribed Opioids to those Not Prescribed Opioids
  • A Forgotten Cause of Bleeding and Musculoskeletal Pain: A Case Report of Contemporary Scurvy
  • A Pilot Clinical and Pharmacokinetic Study of Δ9-Tetrahydrocannabinol (THC) / Cannabidiol (CBD) Nanoparticle Oro-Buccal Spray in Patients with Advanced Cancer Experiencing Uncontrolled Pain.
  • A Rapid Review of Non-Invasive Electromagnetic Devices for the Treatment of Pain
  • A Review of Current Evidence-Based Recommendations of Tramadol for Neuropathic Pain in Adults
  • A Systematic Chemical Design Strategy Leads to NTM-004/005, an Acetaminophen Structural Analog with Minimal Liver Histopathology
  • ADV-484, a Novel Selective Inhibitor of alpha2delta-1 for the Treatment of Neuropathic Pain
  • ADV-502, a Novel Dual Sigma-1 Receptor Antagonist and Mu-Opioid Receptor Agonist for the Treatment of Pain: I. Discovery and Preclinical Evaluation
  • ADV-502, a Novel Dual Sigma-1 Receptor Antagonist and Mu-Opioid Receptor Agonist for the Treatment of Pain: II. Tolerance and Opioid-Induced Hyperalgesia
  • ADV-502, a Novel Dual Sigma-1 Receptor Antagonist and Mu-Opioid Receptor Agonist for the Treatment of Pain: III. Phase-1 Study
  • An epidemiological study of fibromyalgia based on real-world data in a northern city in China
  • Application of Musculoskeletal Ultrasonogram for Same Day Diagnosis and Interventions in the Setting of a Physiatrist’s Office - a Rewarding Experience in Chronic Pain Management.
  • Association between per capita prescribing and abuse of tapentadol and other opioids among individuals entering treatment for opioid use disorders
  • Association of Oral Triptans and Other Common Oral Migraine Treatments With Cardiovascular Outcomes in Patients With a History of Cardiovascular Conditions
  • At-Home Virtual Reality Program for Chronic Low Back Pain: Durability of a Randomized, Placebo-Controlled Trial to 18-months Post-Treatment
  • Atogepant for the preventive treatment of chronic migraine: results from the PROGRESS phase 3 trial
  • Bibliometric Analysis of Camphor and Menthol Containing Topical Anesthetics
  • Brucellosis Bursitis : A not so Uncommon yet so Easily Missed Differential Diagnosis of Knee Pain - A Unique Case Report of Symptomatic Dual Knee Bursitis
  • Capsaicin 8% Topical System combined with Electric cell-Signaling Treatment (EcST) for the treatment of Painful Diabetic Peripheral Neuropathy (PDPN) of the feet: a case series
  • Cebranopadol, a Novel Potent Analgesic: Binding Affinity to Opioid Receptors and In Vitro Activity
  • Cebranopadol, a Novel Potent Analgesic: Limitations in Physical Dependence Using Short- and Long-term Rodent Studies
  • Cebranopadol, a Novel Potent Analgesic: Pooled Analysis of Clinical Opiate Withdrawal Scales
  • Cebranopadol, a Novel Potent Analgesic: Review of Clinical Studies Conducted Across Multiple Types of Pain including Chronic Lower Back Bain, Acute Pain, Diabetic Peripheral Neuropathy, and Cancer Pain
  • Celecoxib Oral Solution in the Acute Treatment of Migraine: Pooled Efficacy and Safety Results From 2 Randomized Placebo-controlled Trials
  • CELECOXIB-TRAMADOL HYDROCHLORIDE CO-CRYSTAL IN PATIENTS WITH MODERATE-TO-SEVERE PAIN FOLLOWING BUNIONECTOMY WITH OSTEOTOMY: SECONDARY ANALYSES OF A PHASE 3, RANDOMIZED, DOUBLE-BLIND, FACTORIAL, ACTIVE- AND PLACEBO-CONTROLLED TRIAL
  • CELECOXIB-TRAMADOL HYDROCHLORIDE CO-CRYSTAL SAFETY, TOLERABILITY, AND DIFFERENTIAL PHARMACOKINETICS: A SUMMARY OF FIVE PHASE 1 RANDOMIZED CLINICAL TRIALS
  • Clinical Value and Utilization of Pharmacologic, Nonpharmacologic and Self-Healing Therapies: A Pilot Study
  • Cocaethylene: When Cocaine Meets Alcohol
  • Comparison of Radiation Dosages for Lumbar Epidural Injections using Midline and Transforminal Approaches.
  • Consistency of Response to Liquid Celecoxib in Adults With Migraine: Post Hoc Analysis of Results From Two Randomized, Placebo-Controlled Studies
  • Cross-sectional Study of Tampering in an Abuse-Deterrent Formulation of an Extended-Release Opioid in a Treatment Center Population
  • Determining the Representativeness of Participants in a Whole Health Interdisciplinary Chronic Pain Program (PREVAIL) in a VA Medical Center: Who Did We Reach?
  • Development of Machine Learning Algorithms Using EEG Features to Detect Presence of Chronic Pain
  • Differences in the severity of medical outcomes of exposures reported to poison centers involving XTAMPZA® ER and other opioid analgesics
  • Does Current Pain Research Reflect Our Diverse Population?
  • DRUG POSITIVITY AND TRENDS IN CLINICAL INQUIRIES FROM A NATIONAL DRUG MONITORING LABORATORY
  • Early Prediction of Response to INP104 for the Acute Treatment of Migraine
  • Effect of outpatient provider type on the rate of emergency department visits for patients with malignant pain
  • Effectiveness of Battlefield Acupuncture on Pain Outcomes at the Carl Vinson VA Medical Center
  • Efficacy of Celecoxib Oral Solution in Adults With and Without Baseline Nausea: Post-Hoc Analysis of Results From Two Randomized, Double-Blind Placebo-Controlled Trials in the Acute Treatment of Migraine
  • Efficacy of Methylnaltrexone in Patients With Advanced Illness And Opioid-Induced Constipation Refractory to Conventional Laxatives: Impact Of Baseline Laxative Use
  • Enkephalin as a Novel Analgesic: Efficacy and Safety in Pre-Clinical Models
  • Evaluating the Literacy Levels of Opioid Agreements
  • Evaluation of Ketamine Infusions in Chronic Pain Patients at TVHS
  • Exploratory Efficacy of INP104 in Migraine Patients By Prior Treatment
  • Exploratory Efficacy of INP104 in Patients Using Concomitant Preventive Migraine Medications
  • Gender Disparity Persists in Pain Medicine: A Cross-Sectional Study of Chairpersons within ACGME-Accredited Chronic Pain Fellowship Programs in the United States
  • Impact of Celecoxib Oral Solution on Symptomatic Improvements in the Acute Treatment of Migraine
  • Impact of Patient Subgroups on the Efficacy of Methylnaltrexone for Opioid-Induced Constipation in Patients With Advanced Illness
  • Improvements in Productivity and Disability With INP104 as Assessed by the Migraine Disability Assessment Scale (MIDAS): Results From the Phase 3 STOP 301 Study
  • LX9211, a Novel Therapeutic Approach to Treatment of Neuropathic Pain
  • Mobile Health Technology & Pain Management
  • Naloxegol Provides Clinically Meaningful Healthcare Related Quality of Life (HR-QOL) Improvement in Patients with Opioid-Induced Constipation (OIC): A Pooled Analysis of Two Global Phase 3 Studies of Naloxegol
  • Naloxegol Provides Clinically Meaningful Symptom Improvement in Patients with Opioid-Induced Constipation (OIC): A Pooled Analysis of Two Global Phase 3 Studies of Naloxegol
  • Non-Medical Use of XTAMPZA ER: Motivation, Methods, and Perceptions of Tampering
  • Opioid Prescription Dispensing Patterns Among Patients With Schizophrenia or Bipolar Disorder
  • OTC Analgesics Knowledge, or Lack Thereof
  • Patterns of Urine Drug Screen Inconsistency in Patients Referred to Establish Care for Chronic Pain: Why are Many Patients Positive for Buprenorphine?
  • Posterior femoral cutaneous nerve neuropathy post marathon: a case report
  • Potent anti-inflammatory effects of an H2S-releasing naproxen (ATB-346) in a human model of inflammation
  • Prescription Opioid Nonmedical Use via Oral Manipulation: An Under-Recognized Risk
  • PREVAIL: Development of a Whole Health Interdisciplinary Evaluation of Chronic Pain in a Rural VA Medical Center
  • Real-World Effectiveness of Ubrogepant for the Acute Treatment of Migraine in Combination With OnabotulinumtoxinA Preventive: Results From the COURAGE Study
  • Response to Treatment with Lemborexant in Older Subjects with Insomnia Disorder and Comorbid Pain at Baseline
  • Selective Inhibition of NaV1.8 with VX-548 as a Targeted Treatment for Acute Pain
  • Targeted Muscle Reinnervation for the Treatment of Complex Regional Pain Syndrome in the Lower Extremity
  • The Agnostic Respiratory Stimulant ENA-001 Demonstrates Preliminary Positive Results in an Animal Model of Apnea of Prematurity
  • The Heat is On: When Hot Weather Hurts
  • The Impact of an Audio-Visual Stimulation Device on Quality of Life and Clinical Symptoms in Participants with Fibromyalgia
  • The Role of Over-the-Counter Pain Relivers for Self-Care in America’s Changing Healthcare Landscape
  • Treatment Effects of Celecoxib Oral Solution in Migraine With Aura and Without Aura: Post-Hoc Analysis of Results From Two Randomized, Double-Blind Placebo-Controlled Trials
  • Treatment of Painful Diabetic Neuropathy (PDN): High-Frequency (10 kHz) Spinal Cord Stimulation (SCS) Provides Significant, Durable Pain Relief for PDN Patients
  • udget Impact Analysis of Xtampza® ER (oxycodone extended-release) for the Treatment of Chronic Pain from a Managed Care Perspective
  • Ultrasound-guided transversus abdominis plane block with liposomal bupivacaine in patients undergoing elective cesarean section via spinal anesthesia
  • Update on NTM-006, a Novel Orally-Active Non-Opioid Analgesic: Molecular-Modeling Consistent with Allosteric Modulation of the Adenosine A3 Receptor
  • When an Old Drug Brings New Challenges: Nitazenes